Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 79 for Metastatic colorectal cancer

Edit search filters
  1. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  2. DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

    Jacksonville, FL

  3. Pemigatinib to Treat Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. A Study of Grapiprant and Pembrolizumab in Patients with Advanced or Progressive MSS Colorectal Cancer

    Scottsdale/Phoenix, AZ

  6. A Study of Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

    Scottsdale/Phoenix, AZ

  7. A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

    Rochester, MN

  9. A Study to Evaluate MM-151, Nal-IRI, 5-FU, and Leucovorin for RAS/RAF Wild-Type Metastatic Colorectal Cancer

  10. Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

    Rochester, MN

.

Mayo Clinic Footer